Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety …

Oct 14, 2025 · Cingulate’s lead candidate, CTx-1301, is in late-stage development for ADHD, with additional candidates in anxiety and other neuropsychiatric indications. Cingulate is headquartered in …

Aug 15, 2025 · "Cingulate remains committed to its mission to bring CTx-1301 to patients with attention-deficit/hyperactivity disorder with its recent new drug application filing submission to the FDA in July.

Nov 13, 2025 · “Cingulate has made meaningful progress this quarter toward key value-creating milestones,” said Jay Roberts, Executive Chairman of Cingulate.

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment Cingulate Inc. Reports Second Quarter …

Nov 13, 2025 · FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date Cingulate Secures …

Cingulate Inc. records deferred income taxes to reflect the impact of temporary differences between the recorded amounts of assets and liabilities for financial reporting purposes and such amounts as …

Oct 23, 2025 · Cingulate’s lead candidate, CTx-1301, is in late-stage development for ADHD, with additional candidates in anxiety and other neuropsychiatric indications. Cingulate is headquartered in …

Leader in Drug Development: Co-founded Cingulate Therapeutics; contributed to FDA approval of 15+ CNS drugs. Academic & Professional Recognition: Clinical Associate Professor at Baylor; published …

Cingulate’s lead candidate, CTx-1301, is in late-stage development for ADHD, with additional candidates in anxiety and other neuropsychiatric indications. Cingulate is headquartered in Kansas City, Kansas. …